Fulgent Genetics, Inc. (FLGT)

NASDAQ: FLGT · IEX Real-Time Price · USD
56.79
+2.07 (3.78%)
At close: Jun 24, 2022 4:00 PM
54.00
-2.79 (-4.91%)
After-hours: Jun 24, 2022 6:23 PM EDT
3.78%
Market Cap 1.72B
Revenue (ttm) 953.42M
Net Income (ttm) 460.65M
Shares Out 30.33M
EPS (ttm) 14.82
PE Ratio 3.83
Forward PE 8.08
Dividend n/a
Ex-Dividend Date n/a
Volume 745,521
Open 54.97
Previous Close 54.72
Day's Range 54.11 - 56.88
52-Week Range 47.34 - 112.00
Beta 1.57
Analysts Buy
Price Target 92.82 (+63.4%)
Earnings Date Aug 8, 2022

About FLGT

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related var... [Read more...]

Industry Health Care Providers & Services
IPO Date Sep 29, 2016
CEO Ming Hsieh
Employees 645
Stock Exchange NASDAQ
Ticker Symbol FLGT
Full Company Profile

Financial Performance

In 2021, FLGT's revenue was $992.58 million, an increase of 135.37% compared to the previous year's $421.71 million. Earnings were $507.36 million, an increase of 136.74%.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for FLGT stock is "Buy." The 12-month stock price forecast is 92.82, which is an increase of 63.44% from the latest price.

Price Target
$92.82
(63.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

2 No-Brainer Stocks to Buy Right Now for Less than $55

These companies have low share prices and high potential.

Other symbols: OM

Fulgent Genetics, Inc. (FLGT) Surpasses Q1 Earnings and Revenue Estimates

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.12% and 6.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics Announces Promotions and Leadership Updates

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient ...

Fulgent Genetics Reports First Quarter 2022 Financial Results

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient ...

Fulgent Genetics Announces Opening of New State-of-the-Art Oncology Laboratory in El Monte, California

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient ...

This Stock Grew 135% Last Year and Is Down 50% From Its Highs

Is Fulgent an underrated stock or a value trap?

AVISTA CAPITAL PARTNERS COMPLETES SALE OF INFORM DIAGNOSTICS TO FULGENT GENETICS, INC.

NEW YORK , April 27, 2022 /PRNewswire/ -- Avista Capital Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced that it has closed on the sale of Inform Di...

Analysts Estimate Fullgent Genetics (FLGT) to Report a Decline in Earnings: What to Look Out for

Fullgent Genetics (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fulgent Genetics (FLGT) to Post Q1 Earnings: What's in Store?

Strategic investments and expanding operations in China are likely to have contributed to Fulgent Genetics' (FLGT) first-quarter performance.

This News Just Put Fulgent at the Top of My Buy List

An acquisition and raised guidance have reinforced the bull case for the stock.

Why Fulgent Genetics Shares Are Trading Higher Today

Fulgent Genetics Inc (NASDAQ: HOTH) agreed to acquire Inform Diagnostics, an independent pathology laboratory based in Irving, Texas, and a portfolio company of Avista Capital Partners, for $170 million...

Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare ...

Fulgent Genetics to Announce First Quarter 2022 Financial Results on Tuesday, May 3, 2022

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in onco...

Got $5,000? Grow It With These 2 Innovative Healthcare Stocks

They're churning out new products while making headway into their massive markets.

Other symbols: ISRG

Is Fulgent Genetics (FLGT) a Suitable Value Investor Stock?

Let's see if Fulgent Genetics (FLGT) stock is a good choice for value-oriented investors right now from multiple angles.

2 Top Biotech Stocks With Huge Potential

Below stocks have been added to my watchlist.

Other symbols: MRNA

Got $5,000? 3 Growth Stocks to Buy That Could Double Your Money

They have a whole lot going right, and little in the way of obstacles.

Other symbols: ABMDDXCM

2 Top Biotech Stocks Ready for a Bull Run

With more to their businesses than COVID-19 revenue, these two companies have huge market opportunities ahead.

Other symbols: MRNA

Representatives of Fulgent Genetics to Participate in Oppenheimer's 32nd Annual Healthcare Conference

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) , a technology-based genetic testing company focused on transforming patient care in onc...

Fulgent Genetics Announces $250 Million Share Repurchase Program

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, inf...

Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of...

IRVINE, Calif., March 7, 2022 /PRNewswire/ -- Helio Health ("Helio"), an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced th...

EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER DefineMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS

SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic brea...

Fullgent Genetics (FLGT) Q4 Earnings and Revenues Surpass Estimates

Fullgent Genetics (FLGT) delivered earnings and revenue surprises of 25.56% and 31.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics,” “Fulgent,” or the “Company”), a technology-based genetic testing company focused on transforming patient ...

Fulgent Genetics Announces Strategic Investment in Spatial Genomics

TEMPLE CITY, Calif. & PASADENA, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient ca...